Shirleysmith
New Member
While ivermectin has shown promising anti-cancer effects in various preclinical studies, there is currently limited data on the optimal dosage for human cancer treatment. The effective doses used in animal studies ranged from 2.4 to 40 mg/kg, administered via intraperitoneal or intratumoral injection[1][4]. These doses were able to reduce tumor volumes by up to 85% in certain cancer models[1].
However, it is important to note that the doses used in animal studies may not directly translate to safe and effective doses for humans. A phase I pharmacokinetic study suggested that Ivermectin Medicine up to 2 mg/kg is tolerable in humans[2]. Based on this, the concentrations of ivermectin used in preclinical cell culture models, typically ranging from 1-30 μM, appear to be clinically relevant[2][3]. While these findings are promising, further research is needed to determine the optimal dosing regimen and route of administration for ivermectin in cancer patients. It is crucial for individuals to consult with their healthcare provider before considering any off-label use of ivermectin for cancer treatment.
However, it is important to note that the doses used in animal studies may not directly translate to safe and effective doses for humans. A phase I pharmacokinetic study suggested that Ivermectin Medicine up to 2 mg/kg is tolerable in humans[2]. Based on this, the concentrations of ivermectin used in preclinical cell culture models, typically ranging from 1-30 μM, appear to be clinically relevant[2][3]. While these findings are promising, further research is needed to determine the optimal dosing regimen and route of administration for ivermectin in cancer patients. It is crucial for individuals to consult with their healthcare provider before considering any off-label use of ivermectin for cancer treatment.